Modulim, the leader in point of care microvascular insights, announced the grant of United States Patent US11751769B2, titled “Systems and Methods for Assessing Diabetic Circulatory Complications.” This patent signifies a milestone for Modulim and the relevance of its solutions for diabetes patient management.
The patent teaches Modulim’s novel approach to assess circulatory complications with proprietary biomarkers, and how it can provide an assessment of at-risk diabetes patients with a single snapshot. The underlying SFDI technology leverages structured light projection within the visible and near-infrared regime, and model-based mapping of circulation-informing chromophores, such as hemoglobin, in skin.
Modulim is excited to contribute to the advancement of diabetes healthcare, and is actively seeking collaborations and partnerships within the healthcare industry to maximize the potential of this innovative technology.
About Modulim
Modulim delivers transformative health technology solutions that empower clinicians across the continuum of care to improve patient outcomes. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, quantifies and maps tissue health at the point-of-care through non-contact rapid microvascular assessment. Modulim Cloud™ promotes timely, proactive data-driven decisions to reduce lower-limb complications by digitally connecting clinicians and healthcare systems. Modulim is based in Irvine, CA, with a team dedicated to delivering powerful healthcare solutions that elevate the standard of care for patients with diabetes, kidney disease, and peripheral vascular disease.
Clarifi is a registered trademark of Modulated Imaging (dba Modulim).
Contact:
Modulim
Blake Byrne
bbyrne@modulim.com